How far have we come in cord blood cell expansion technologies? Scientists at the leading edge of the research will explain their progress and what may lie ahead in a session at the Cord Blood Connect international congress.
“Many of you have been following the development of cord blood expansion technology,” said Mitchell Horwitz, director of adult blood and marrow transplantation at Duke University School of Medicine, who will be chairing the session.
“Two technologies that seem to be leading the way in clinical development are omidubicel and UM171. We will hear about those and also about the early development of an off-the-shelf product that addresses many of the logistical issues of cord blood expansion,” he said.
Much of the progress to be presented at the congress will be new, yet-to-be-published studies and data.
“This is going to be a great session,” Dr. Horwitz said. “I think it will be of interest not only to those who are clinicians, but also to cord blood bankers and scientists. There will be plenty of time for discussion after the presentations. We really want to encourage audience participation.”
The session, “Expansion of Cord Blood Cells – New Horizons for Cord Blood Transplantation,” will be at 1:30 pm Friday, Sept. 9.